We also report here that MG132 has beneficial effects, reversing cellular pathological phenotypes in HGPS fibroblasts and decreasing progerin and SRSF‐1 levels in iPSC‐derived MSC and VSMC from HGPS patients' fibroblasts. This evidence concerns the gene SRSF1 and Hutchinson-Gilford progeria syndrome.